Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab and Atezolizumab in Advanced Solid Tumours
NCT06003621Phase 2Active, not recruiting
- Sponsor
- Omico
- Start
- Dec 2023
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tiragolumab in solid tumor, sponsored by Omico. Primary endpoint: Progression Free Survival rate at 6 months. Started Dec 2023; status: active, not recruiting.
02
Drugs
tiragolumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06003621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003621.